Barclays initiated coverage on Xeris Biopharma with a new price target
$XERS
Biotechnology: Pharmaceutical Preparations
Health Care
Barclays initiated coverage of Xeris Biopharma with a rating of Overweight and set a new price target of $9.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2025 | $9.00 | Overweight | Barclays |
| 8/12/2025 | $10.00 | Buy | H.C. Wainwright |
| 11/11/2024 | $3.00 | Overweight → Neutral | Piper Sandler |
| 3/28/2024 | $5.00 | Outperform | Oppenheimer |
| 8/28/2023 | $4.50 | Buy | Craig Hallum |
| 10/21/2022 | $4.00 | Buy | Jefferies |
| 4/28/2022 | $6.50 | Buy | Craig Hallum |
| 2/16/2022 | $8.00 → $6.00 | Outperform | SVB Leerink |
144 - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
S-8 - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
10-K - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
Barclays initiated coverage of Xeris Biopharma with a rating of Overweight and set a new price target of $9.00
H.C. Wainwright resumed coverage of Xeris Biopharma with a rating of Buy and set a new price target of $10.00
Piper Sandler downgraded Xeris Biopharma from Overweight to Neutral and set a new price target of $3.00
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
Achieved record quarterly and full-year total revenue of $86 million and $292 million, respectively Provides full year 2026 total revenue guidance range of $375 million to $390 million Hosts conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provides financial guidance for full year 2026. "Thanks to the entire Xeris organization, 2025 was a transformational year, marked by focused e
Four Orange Book Listed Patents through March 2040 Orphan Drug Exclusivity through December 2028 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, announced that its subsidiaries, Xeris Pharmaceuticals, Inc. and Strongbridge Dublin Limited, have filed a patent infringement lawsuit under the Hatch-Waxman Act related to Recorlev® (levoketoconazole) in the United States District Court for the District of New Jersey against Torrent Pharmaceuticals Limited (along with its affiliate) and Somerset Therapeutics, LLC (along with its affiliat
Conference Call to be Held at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full year 2025 financial results before the open of the U.S. financial markets on Monday, March 2, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. To pre-register for the call, please go to the following link: https://events.q4inc.com/analyst/428274643?pwd=TZMrH35H Afte
Achieved record quarterly and full-year total revenue of $86 million and $292 million, respectively Provides full year 2026 total revenue guidance range of $375 million to $390 million Hosts conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provides financial guidance for full year 2026. "Thanks to the entire Xeris organization, 2025 was a transformational year, marked by focused e
Conference Call to be Held at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full year 2025 financial results before the open of the U.S. financial markets on Monday, March 2, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. To pre-register for the call, please go to the following link: https://events.q4inc.com/analyst/428274643?pwd=TZMrH35H Afte
Conference Call to be Held at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its third quarter 2025 financial results before the open of the U.S. financial markets on Thursday, November 6, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. To pre-register for the call, please go to the following link: https://www.netroadshow.com/events/login/LE9zwo3lV0p4Y9XVAt3dNbajZlK6unm
SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ
Kenneth Johnson, PharmD, SVP Global Development & Medical Affairs to retire Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that Dr. Anh Nguyen has joined Xeris as Chief Medical Officer (CMO) succeeding Ken Johnson PharmD, SVP, Global Development and Medical Affairs who will retire April 1, 2025. Dr. Nguyen will develop and lead the entire product portfolio vision and strategic direction for the Medical, Regulatory, Preclinical and Clinical Development, and Pharmacovigilance functions, reporting to John Shannon, X
John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track record of its leadership team Q2 '24 total revenue is anticipated to exceed $47 million, representing more than 23% growth over last year Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced a CEO succession plan effective August 1, 20
SC 13G - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
SC 13G/A - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
SC 13G - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)